Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [8]. Group 2: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the FDA regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Nidec Corporation is under investigation for potential improper accounting practices, leading to significant stock price declines and investor losses [5][6][7]. Group 1: Investigation and Findings - On September 3, 2025, Nidec announced the establishment of a third-party committee to investigate suspicions of improper accounting, revealing documents suggesting management involvement in these practices [5]. - On September 26, 2025, Nidec disclosed further findings of inappropriate accounting, including undervaluation for customs purposes, and received an audit report with a disclaimer of opinion due to ongoing investigations [6]. - On October 23, 2025, Nidec withdrew its year-end forecast and decided not to pay a surplus dividend, citing ongoing investigations into suspected accounting practices [7]. Group 2: Stock Price Impact - Following the announcement on September 4, 2025, Nidec's stock price fell by $0.81, or 16.5%, closing at $4.11 per share [5]. - After the September 26 disclosure, the stock price decreased by $0.29, or 6.6%, closing at $4.09 per share [6]. - On October 23, 2025, the stock price dropped by $1.17, or 25.4%, closing at $3.43 per share [7]. - On October 27, 2025, the stock price fell by $0.80, or 20.3%, closing at $3.15 per share following a designation under a Special Security alert by the Tokyo Stock Exchange [8][9]. Group 3: Regulatory Response - The Tokyo Stock Exchange designated Nidec under a Special Security alert, indicating a need for significant improvement in the company's internal management systems and identifying deficiencies in internal controls related to accounting and financial processes [8].

Core Points - Rosen Law Firm is encouraging WPP plc investors who incurred losses exceeding $100,000 during the Class Period from February 27, 2025, to July 8, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][2]. Group 1: Legal Action Details - Investors who purchased WPP ADSs during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must apply to serve as lead plaintiff by December 8, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 2: Case Background - The complaint alleges that WPP's management made overly positive statements while concealing material adverse facts about the company's media arm, which was reportedly unprepared for macroeconomic challenges and losing market share [5].

Core Points - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the Class Period from May 16, 2024, to August 5, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][5]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in securing significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant reduction in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to alleged misleading statements and health risks associated with the company's glucose monitoring systems [2][3][6]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members [4]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [6]. - The situation has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Cepton, Inc. who experienced losses exceeding $100,000 during the specified Class Period to secure legal counsel before the December 8, 2025 deadline for lead plaintiff applications in a securities class action lawsuit [2][4]. Group 1: Class Action Details - The Class Period for the Cepton securities class action is from July 29, 2024, to January 6, 2025 [2]. - Investors who purchased or sold Cepton common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must apply by December 8, 2025, to serve as lead plaintiff, representing other class members [4]. Group 2: Allegations Against Cepton - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations [6]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [6]. - The Board of Directors allegedly failed to explore this offer meaningfully and did not disclose its terms, depriving shareholders of the opportunity to consider the acquisition [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a Wall Street Journal article published on October 29, 2025, which reported that Hormel Foods cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility [3]. - Following the news, Hormel Foods' stock experienced a significant decline of 9.1% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Hormel securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].